Market Overview:
The global triple-negative breast cancer treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of triple-negative breast cancer, rising awareness about available treatments, and growing demand for targeted therapies. Triple-negative breast cancer is an aggressive form of the disease that does not respond to hormonal therapy or chemotherapy drugs that target estrogen receptors or HER2 proteins. The most common treatment for triple-negative breast cancer is chemotherapy, which can include drugs such as doxorubicin (Adriamycin), cyclophosphamide (Cytoxan), and paclitaxel (Taxol). Other treatments options include radiation therapy, surgery, and targeted therapies such as trastuzumab (Herceptin) and lapatinib (Tykerb). The alkylating agents segment accounted for the largest share of the global triple-negative breast cancer treatment market in 2017. This segment includes drugs such as doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan), which are used to treat a wide range of cancers including triple-negative breast cancer. The plant products segment is expected to grow at the highest CAGR during the forecast period from 2018 to 2030 due to increasing demand for natural products as alternatives to conventional chemotherapeutic agents.
Product Definition:
Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptors. This means that the tumor cells do not have these proteins on their surface, which limits treatment options. Although current treatments are available, there is no known cure for triple-negative breast cancer.
Alkylating Agents:
Alkylating agents are a group of chemicals that act as strong carcinogens. Alkylating agents change the normal functioning of cells in the body and lead to uncontrolled growth of cancerous cells. Some examples of alkylating agents include nitrogen mustards, proton beam radiation therapy, busulfan, and some chemotherapy drugs such as 5-fluorouracil (Adrucil), which is commonly used in breast cancer treatment.
Plant Products:
Plant products and it's usage in Triple-Negative Breast Cancer Treatment market is expected to witness significant growth over the forecast period. Increasing demand for natural ingredients coupled with their effectiveness is anticipated to drive the growth of plant products & it's derivatives in triple negative breast cancer treatment market. Plant derived active compounds are being extensively used as alternatives for cytotoxic drugs which have been identified as a major cause of side effects such as nausea, hair loss, fatigue, etc. The U.
Application Insights:
The hospital pharmacies segment dominated the global triple-negative breast cancer treatment market in 2017. This can be attributed to factors such as presence of a large number of hospitals, which are major healthcare providers and have onsite pharmacies, availability of advanced healthcare facilities with 24/7 skilled care services and easy access to medication through retail outlets.
Moreover, key players in the market are manufacturing generic drugs for various applications including cancer treatment; this is anticipated to further boost growth over the forecast period. For instance, Pfizer manufactures Alimta (Pemetrexed & Cisplatin) for patients suffering from metastatic breast carcinoma who have not been able to undergo chemotherapy or cannot tolerate it due to its adverse effects.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of advanced treatment options, high healthcare expenditure and awareness campaigns regarding breast cancer diagnosis & treatment. Moreover, increasing R&D activities by various organizations is expected to fuel growth during the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India. Furthermore, growing medical tourism industry due to low cost treatments offered by local hospitals will also boost revenue generation in this region over the next eight years.
Growth Factors:
- Increasing incidence of triple-negative breast cancer
- Growing awareness about triple-negative breast cancer and its treatment options
- Rising demand for targeted therapies for triple-negative breast cancer
- Technological advancements in the field of triple-negative breast cancer treatment
- increasing investment in research and development for novel therapies for triple-negative breast cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Triple-Negative Breast Cancer Treatment Market Research Report
By Type
Alkylating Agents, Plant Products, Microorganism Products, Antimetabolites, Microtubule Stablizing Agents
By Application
Hospital Pharmacies, Retail Pharmacies
By Companies
Celgene, Roche, Immunomedics GmbH, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Eisai Co., Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Triple-Negative Breast Cancer Treatment Market Report Segments:
The global Triple-Negative Breast Cancer Treatment market is segmented on the basis of:
Types
Alkylating Agents, Plant Products, Microorganism Products, Antimetabolites, Microtubule Stablizing Agents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Roche
- Immunomedics GmbH
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Eisai Co., Ltd
Highlights of The Triple-Negative Breast Cancer Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alkylating Agents
- Plant Products
- Microorganism Products
- Antimetabolites
- Microtubule Stablizing Agents
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Triple-Negative Breast Cancer Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Triple-negative breast cancer is a type of breast cancer that cannot be treated with traditional chemotherapy or radiation. Triple-negative breast cancer cells do not respond to any of the standard treatments for breast cancer.
Some of the key players operating in the triple-negative breast cancer treatment market are Celgene, Roche, Immunomedics GmbH, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Eisai Co., Ltd.
The triple-negative breast cancer treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Triple-Negative Breast Cancer Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Triple-Negative Breast Cancer Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Triple-Negative Breast Cancer Treatment Market - Supply Chain
4.5. Global Triple-Negative Breast Cancer Treatment Market Forecast
4.5.1. Triple-Negative Breast Cancer Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Triple-Negative Breast Cancer Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Triple-Negative Breast Cancer Treatment Market Absolute $ Opportunity
5. Global Triple-Negative Breast Cancer Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Type
5.3.1. Alkylating Agents
5.3.2. Plant Products
5.3.3. Microorganism Products
5.3.4. Antimetabolites
5.3.5. Microtubule Stablizing Agents
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Triple-Negative Breast Cancer Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Triple-Negative Breast Cancer Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Triple-Negative Breast Cancer Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Triple-Negative Breast Cancer Treatment Demand Share Forecast, 2019-2026
9. North America Triple-Negative Breast Cancer Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Type
9.7.1. Alkylating Agents
9.7.2. Plant Products
9.7.3. Microorganism Products
9.7.4. Antimetabolites
9.7.5. Microtubule Stablizing Agents
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Triple-Negative Breast Cancer Treatment Demand Share Forecast, 2019-2026
10. Latin America Triple-Negative Breast Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Type
10.7.1. Alkylating Agents
10.7.2. Plant Products
10.7.3. Microorganism Products
10.7.4. Antimetabolites
10.7.5. Microtubule Stablizing Agents
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Triple-Negative Breast Cancer Treatment Demand Share Forecast, 2019-2026
11. Europe Triple-Negative Breast Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Type
11.7.1. Alkylating Agents
11.7.2. Plant Products
11.7.3. Microorganism Products
11.7.4. Antimetabolites
11.7.5. Microtubule Stablizing Agents
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Triple-Negative Breast Cancer Treatment Demand Share, 2019-2026
12. Asia Pacific Triple-Negative Breast Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Type
12.7.1. Alkylating Agents
12.7.2. Plant Products
12.7.3. Microorganism Products
12.7.4. Antimetabolites
12.7.5. Microtubule Stablizing Agents
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Triple-Negative Breast Cancer Treatment Demand Share, 2019-2026
13. Middle East & Africa Triple-Negative Breast Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Triple-Negative Breast Cancer Treatment Market Size and Volume Forecast by Type
13.7.1. Alkylating Agents
13.7.2. Plant Products
13.7.3. Microorganism Products
13.7.4. Antimetabolites
13.7.5. Microtubule Stablizing Agents
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Triple-Negative Breast Cancer Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Triple-Negative Breast Cancer Treatment Market: Market Share Analysis
14.2. Triple-Negative Breast Cancer Treatment Distributors and Customers
14.3. Triple-Negative Breast Cancer Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Celgene
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Roche
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Immunomedics GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck & Co., Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. F. Hoffmann-La Roche Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eisai Co., Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
